Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Experience using cefpirome in pneumonia]

Iu B Belousov, A B Gudkin, G N Izotova

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |January 1, 1996
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Efficacy and safety of topical antibiotic therapy in patients with acute external bacterial otitis: results of a retrospective study].

    Vestnik otorinolaringologii·2024
    Same author

    [Modern pharmacotherapy of acute bacterial sinusitis: results of an open randomized clinical trial of the therapeutic equivalence of Cefixime EXPRESS and Suprax Solutab].

    Vestnik otorinolaringologii·2024
    Same author

    [Efficacy and safety of topical combination therapy in patients with acute otitis externa].

    Terapevticheskii arkhiv·2023
    Same author

    [Hearing care aspects in universal face mask use during the COVID 19 pandemic].

    Vestnik otorinolaringologii·2021
    Same author

    [The use of Gliathiline in patients with sensorineural hearing loss].

    Vestnik otorinolaringologii·2020
    Same author

    [Results of the observational (non-interventional) research 'Analysis of therapeutic efficiency of the polyvalent Piobacteriophag (Secstaphag) in the treatment of acute sinusitis'].

    Vestnik otorinolaringologii·2019
    Same journal

    New Data on Molecular Targets of Tamoxifen Besides Estrogen Receptors, Their Clinical Significancy.

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2018
    Same journal

    Interferon-Gamma: Treatment Horizons.

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2018
    Same journal

    Plant Extracts in Development of Medicinal Products of Various Therapeutic Value.

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2018
    Same journal

    Macrolide Resistance and Its Molecular Genetic Mechanisms in Streptococcus pyogenes Isolated from Children.

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2018
    Same journal

    Experimental Substantiation of Taurine Use in Prophylaxis of Isoniazid-Induced Neurotoxic Reactions.

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2018
    Same journal

    Biologically Active Substances from Marine Hydrobionts with Antibacterial Activity in Composition of New Wound Dressings.

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2018
    See all related articles

    Cefpirome effectively treated lower respiratory tract infections in 80% of patients, demonstrating good tolerance in 95%. Bacterial isolates showed high susceptibility to this antibiotic, supporting its use in pneumonia and chronic bronchitis.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Respiratory Medicine

    Background:

    • Lower respiratory tract infections (LRTI) pose significant health challenges.
    • Pneumonia and chronic bronchitis are common forms of LRTI, often with comorbidities.
    • Antibiotic resistance necessitates evaluation of effective treatment options.

    Purpose of the Study:

    • To evaluate the clinical efficacy and safety of cefpirome in patients with LRTI.
    • To assess the susceptibility of bacterial isolates to cefpirome in this patient cohort.

    Main Methods:

    • A cohort of twenty patients with LRTI (16 pneumonia, 4 chronic bronchitis) received intravenous cefpirome.
    • Dosage: 1 gram twice daily for 7–10 days.
    • Clinical outcomes, drug tolerance, and microbiological susceptibility were assessed.

    Related Experiment Videos

    Main Results:

    • Clinical efficacy was observed in 80% of treated patients.
    • Cefpirome demonstrated good drug tolerance in 95% of cases.
    • Bacterial isolates exhibited an 83% susceptibility rate to cefpirome.

    Conclusions:

    • Cefpirome is an effective and well-tolerated treatment for lower respiratory tract infections, including pneumonia and chronic bronchitis.
    • High in vitro susceptibility suggests cefpirome's utility against common respiratory pathogens.
    • Further research may explore cefpirome's role in managing complex LRTI cases.